BioSpace News Archive

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q3 2020, before the U.S. markets open on Thursday, November 5, 2020.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that members of management will participate in the Virtual Investor KOL Roundtable on Thursday, October 29, 2020 at 10:00 AM ET. Participating in the KOL Roundtable discussion will be Lawrence Kenyon, Presiden

Amendment includes additional task to develop yeast beta glucan as an inhalable therapeutic for COVID-19

Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it will present on Day 1 of the Virtual Diabetes Technology Meeting 2020 on November 12, 2020 at 2:50 PT. Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will give a presentation ti

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its third quarter 2020 operating results on Wednesday, November 4 , 2020 at 8 :30 a.m. EDT . The conference call will be hosted by TRHC CEO, Chairman and Founder, Calvin H. Knowlton, Ph.D.; TRHC Co-Founder, President, Chief Marketing and Business Development Officer, Orsula V. Knowlton, PharmD, MBA; and TRHC Chief Financial Officer, Brian W

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced the appointment of Shelley Broader to the Board of Directors.

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that the first patient has been dosed in the Phase 1/2 GRECO-1 clinical trial of GC4711 in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCL

Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, In

Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.

- Massachusetts signs proclamation declaring Oct.23 as AADC Deficiency Awareness Day - - PTC hosts Facebook Live event featuring leaders from AADC Family Network, MassBio, and Boston Children’s Hospital -